# OnCo record shared-antigen-vaccine (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/shared-antigen-vaccine/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "shared-antigen-vaccine" ;
  schema:name "Off-the-shelf cancer vaccines"@en ;
  schema:description "Off-the-shelf cancer vaccines target antigens shared across patients, such as mutant KRAS or HER2 peptides, so they are made in advance rather than per person. Sipuleucel-T is still the only approved therapeutic cancer vaccine in the US; tolerance to self-antigens and weak past results hold them back."@en ;
  schema:url <https://onco.cc/technologies/shared-antigen-vaccine/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-19-3517>, <https://clinicaltrials.gov/study/NCT05726864> ;
  onco:status "phase-3" ;
  onco:related <https://onco.cc/ideas/idea-splice-neoantigens/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/gritstone/>, <https://onco.cc/companies/adventris-pharmaceuticals/>, <https://onco.cc/companies/curevac/>, <https://onco.cc/companies/evaxion/>, <https://onco.cc/companies/guardian-bio/>, <https://onco.cc/companies/io-biotech/>, <https://onco.cc/companies/mendus/>, <https://onco.cc/companies/nykode-therapeutics/>, <https://onco.cc/companies/ose-immunotherapeutics/>, <https://onco.cc/companies/tarebio/> .